All Stories

  1. ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation

    Article • npj Breast Cancer, November 2023, Springer Science + Business Media

    Professor Geoffrey L Greene

  2. Glucocorticoid Receptor Activation in Lobular Breast Cancer Is Associated with Reduced Cell Proliferation and Promotion of Metastases

    Article • Cancers, September 2023, MDPI AG

    Professor Geoffrey L Greene

  3. Supplemental Materials and Methods and Figure Legends from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers

    Article • April 2023, American Association for Cancer Research (AACR)

    Professor Geoffrey L Greene

  4. Supplemental Materials and Methods and Figure Legends from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers

    Article • April 2023, American Association for Cancer Research (AACR)

    Professor Geoffrey L Greene

  5. Supplemental Table 1 from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers

    Article • April 2023, American Association for Cancer Research (AACR)

    Professor Geoffrey L Greene

  6. Supplemental Table 1 from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers

    Article • April 2023, American Association for Cancer Research (AACR)

    Professor Geoffrey L Greene

  7. Supplemental Table 2 from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers

    Article • April 2023, American Association for Cancer Research (AACR)

    Professor Geoffrey L Greene

  8. Supplemental Table 2 from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers

    Article • April 2023, American Association for Cancer Research (AACR)

    Professor Geoffrey L Greene

  9. Supplemental Table 3 from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers

    Article • April 2023, American Association for Cancer Research (AACR)

    Professor Geoffrey L Greene

  10. Supplemental Table 3 from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers

    Article • April 2023, American Association for Cancer Research (AACR)

    Professor Geoffrey L Greene

  11. Supplementary Figures 1-6 from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers

    Article • April 2023, American Association for Cancer Research (AACR)

    Professor Geoffrey L Greene

  12. Supplementary Figures 1-6 from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers

    Article • April 2023, American Association for Cancer Research (AACR)

    Professor Geoffrey L Greene

  13. Data from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers

    Article • April 2023, American Association for Cancer Research (AACR)

    Professor Geoffrey L Greene

  14. Data from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers

    Article • April 2023, American Association for Cancer Research (AACR)

    Professor Geoffrey L Greene

  15. Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells

    Article • npj Breast Cancer, December 2022, Springer Science + Business Media

    Professor Geoffrey L Greene

  16. Targeting MYC with modular synthetic transcriptional repressors derived from bHLH DNA-binding domains

    Article • Nature Biotechnology, October 2022, Springer Science + Business Media

    Professor Geoffrey L Greene

  17. Unconventional Isoquinoline-Based SERMs Elicit Fulvestrant-Like Transcriptional Programs in ER+ Breast Cancer Cells

    Article • August 2022, Research Square

    Professor Geoffrey L Greene

  18. Labeling of a Mutant Estrogen Receptor with an Affimer in a Breast Cancer Cell Line

    Article • Biophysical Journal, June 2022, Elsevier

    Professor Geoffrey L Greene

  19. Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells

    Article • Cancers, May 2022, MDPI AG

    Professor Geoffrey L Greene

  20. Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer

    Article • Molecular Cancer Research, May 2021, American Association for Cancer Research (AACR)

    Professor Geoffrey L Greene

  21. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer

    Article • May 2021, Springer Science + Business Media

    Professor Geoffrey L Greene

  22. Reinvestigating the acyl cyclization to the precursor of diptoindonesin G

    Article • Tetrahedron Letters, April 2021, Elsevier

    Professor Geoffrey L Greene

  23. Facilitating Drug Discovery in Breast Cancer by Virtually Screening Patients Using In Vitro Drug Response Modeling

    Article • Cancers, February 2021, MDPI AG

    Professor Geoffrey L Greene

  24. The NFκB pathway promotes tamoxifen tolerance and disease recurrence in estrogen receptor positive breast cancers

    Article • Molecular Cancer Research, April 2020, American Association for Cancer Research (AACR)

    Professor Geoffrey L Greene

  25. Next Generation ERα Inhibitors for Endocrine-Resistant ER+ Breast Cancers

    Article • Endocrinology, February 2019, Endocrine Society

    Professor Geoffrey L Greene

  26. Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity

    Article • Nature Communications, June 2018, Springer Science + Business Media

    Professor Geoffrey L Greene

  27. Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance

    Article • Nature Reviews Cancer, April 2018, Springer Science + Business Media

    Professor Geoffrey L Greene

  28. A “cross-stitched” peptide with improved helicity and proteolytic stability

    Article • Organic & Biomolecular Chemistry, January 2018, Royal Society of Chemistry

    Professor Geoffrey L Greene

  29. Metabolism of megestrol acetate in vitro and the role of oxidative metabolites

    Article • Xenobiotica, November 2017, Taylor & Francis

    Professor Geoffrey L Greene

  30. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer

    Article • Science Advances, June 2016, American Association for the Advancement of Science

    Professor Geoffrey L Greene

  31. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation

    Article • eLife, February 2016, eLife

    Professor Geoffrey L Greene

  32. In Memoriam: Elwood Jensen (1920–2012)

    Article • Endocrinology, October 2013, Endocrine Society

    Professor Geoffrey L Greene

  33. Overcoming mutation-based resistance to antiandrogens with rational drug design

    Article • eLife, April 2013, eLife

    Yang Shen, Dr CHARLES L SAWYERS, Professor Geoffrey L Greene